Form 4: Oruka Therapeutics Director Samarth Kulkarni Granted 17,500 Stock Options

Oruka Therapeutics, Inc. Director Samarth Kulkarni was granted 17,500 stock options with an exercise price of $11.77, vesting monthly from June 2, 2025.

Summary

• Samarth Kulkarni, a Director of Oruka Therapeutics, Inc. (ORKA), acquired 17,500 stock options.
• The stock options have an exercise price of $11.77 per share.
• The options begin vesting on June 2, 2025, with 1/12 of the underlying shares vesting monthly.
• The expiration date for these stock options is June 1, 2035.
• Following this transaction, Mr. Kulkarni directly beneficially owns 17,500 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options is a positive signal for aligning management incentives with shareholder value, though it is a routine compensation event and not indicative of extraordinary company performance.

Positives

• The grant of stock options to Director Samarth Kulkarni aligns his interests with those of shareholders, as the value of the options is tied to the company's stock performance.
• The options have a long expiration date of June 1, 2035, providing a significant window for potential value realization.

Risks

• The value of the granted stock options is subject to the future market price of Oruka Therapeutics, Inc. common stock. If the stock price does not exceed the exercise price of $11.77, the options may expire worthless.

Future Outlook

The stock options will vest monthly starting from June 2, 2025, over a 12-month period, allowing the director to gradually exercise them over time, subject to the company's stock performance.

Industry Context

The grant of stock options is a standard and widely adopted practice in the biotechnology and pharmaceutical industries, as well as across many other sectors, for compensating directors and executives. It serves to incentivize long-term performance and align management's financial interests with shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to a director is a common form of executive and board compensation across publicly traded companies, including those in the biotech sector like Oruka Therapeutics.
• While specific grant sizes and exercise prices vary based on company size, stage, and individual roles, the mechanism itself is standard.
• Similar compensation structures are observed at companies like Moderna (MRNA) or BioNTech (BNTX) for their board members, though the scale would differ significantly based on market capitalization and compensation philosophy.
• The vesting schedule (monthly over 12 months) is also a typical approach to encourage retention and sustained performance.

Related Party Transactions

• The grant of stock options to Samarth Kulkarni, a Director of Oruka Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with shareholders, potentially leading to better long-term performance. Future exercise of options could lead to minor dilution.
• Director (Samarth Kulkarni): Receives a significant component of compensation tied to the company's future stock performance, providing a direct financial incentive.

Next Steps

• The stock options will begin their monthly vesting schedule from June 2, 2025.

Key Dates

Keywords

Oruka Therapeutics, ORKA, Form 4, stock options, insider transaction, beneficial ownership, director compensation, equity compensation